Current Research Studies

A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less than 18 Years of Age with Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

AWARD-PEDS PLUS

Phase: III
Clinicaltrials.gov ID: NCT06739122

What is the goal of the study?

Study H9X-MC-GBGS is a Phase 3, open-label, multicenter, single-arm study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of dulaglutide 3.0 mg and 4.5 mg in pediatric participants 10 to less than 18 years of age with type II diabetes mellitus

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Petter Bjornstad
Study Team Member: Kevin Bocek, [email protected]